[Axillary lymph node recurrence after sentinel lymph node biopsy for breast cancer]

Area of Science:

• Oncology
• Surgical Pathology
• Breast Cancer Research

Context:

• Sentinel lymph node (SLN) biopsy is a standard staging procedure for early-stage invasive breast cancer.
• Accurate axillary nodal status evaluation is crucial for treatment planning and prognosis.
• Understanding axillary recurrence rates after SLN biopsy informs clinical decision-making.

Purpose:

• To review and synthesize current literature on axillary recurrence following SLN biopsy in breast cancer patients.
• To evaluate the reliability and outcomes of the SLN procedure for axillary staging.
• To identify factors influencing axillary recurrence and potential strategies for optimization.

Summary:

• The SLN biopsy is a reliable method for assessing axillary nodal status in selected early-stage breast cancer patients.
• When the SLN is pathologically negative, axillary recurrence rates range from 0% to 2% with follow-up up to 57 months.
• For SLNs with isolated tumor cells or micrometastases, complete axillary lymph node dissection is recommended to minimize recurrence risk.
• Intraoperative gamma cameras may enhance SLN procedure accuracy and reduce axillary recurrences.

Impact:

• SLN biopsy provides accurate staging, potentially avoiding complete axillary dissection in node-negative patients.
• Low recurrence rates confirm the efficacy of SLN biopsy in appropriate patient selection.
• Further research into optimizing SLN procedures, including advanced imaging, can improve oncologic outcomes and patient care.